Intravitreal bevacizumab for age-related macular degeneration with good visual acuity
- First Online:
- 95 Downloads
To retrospectively study the efficacy of intravitreal bevacizumab (IVB) for exudative age-related macular degeneration (AMD) in patients with good visual acuity (VA).
Fifteen eyes of 15 patients (mean age, 69.0 ± 11.3 years) with AMD whose VA was 0.6 or better were treated with IVB 1.25 mg/0.05 ml. The patients were followed for 12 to 29 months (mean, 17.4 ± 4.9 months).
Best-corrected visual acuity (BCVA) ranged from 0.6 to 1.2 (mean, 0.89 ± 0.21) at baseline and was stable in 13 of 15 eyes (86.7%) when BCVA was 0.6 or better at the end of follow-up. The VA levels did not differ significantly (P = 0.42; paired t test) between baseline and the final examination. Two of the 15 eyes underwent photodynamic therapy during follow-up. The mean central retinal thickness significantly decreased from 278.4 ± 71.9 μm at baseline to 240.00 ± 58.5 μm at 3 months after the first IVB treatment (P = 0.02; Wilcoxon signed rank test). During follow-up, a mean of two injections was administered, and 47% of patients required only one injection. No adverse events developed.
IVB was effective for maintaining good vision in exudative AMD in 15 eyes for at least 12 months.
Keywordsage-related macular degeneration anti-VEGF therapy choroidal neovascularization good visual acuity intravitreal bevacizumab injection
Unable to display preview. Download preview PDF.
- 1.Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese Age-Related Macular Degeneration Trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1049–1061.CrossRefGoogle Scholar
- 2.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report 1. Arch Ophthalmol 1999;117:1329–1345.Google Scholar
- 3.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 2001;119:198–207.Google Scholar
- 4.Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541–560.CrossRefGoogle Scholar
- 5.Treatment of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol 2003;136:407–418.CrossRefGoogle Scholar
- 6.Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, and Verteporfin in Photodynamic Therapy (VIP) Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials—TAP and VIP report no. 3. Am J Ophthalmol 2004;137:683–696.CrossRefGoogle Scholar
- 8.VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, Chakravathy U, Adamis AP, Cunningham ET Jr, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508–1521.Google Scholar
- 11.Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912–918.Google Scholar